Praxsyn Announces Progress in Filing of Form 10-Q

IRVINE, Calif., June 23, 2014 -- Praxsyn Corporation (OTCQB:PXYN), a medication and service provider for medical practitioners, announced that it is making progress in filing its Form 10-Q for the quarter ended March 31, 2014.

"The work on the first quarter 10-Q continues and is meeting our internal completion deadlines," said Dan O'Brien, CFO, Praxsyn Corporation. "Our continued work requires the accounting team to conduct detailed research and confirm many historical facts and figures for several entities' most important accounts throughout the years 2012 and 2013, as well as the first quarter of 2014, which will then be submitted to our auditor. Based upon our ability to continue to complete this work and assuming continued progress at a similar rate, we hope to have all material information required for the 10-Q filing to our auditor by June 27, 2014."

Praxsyn Announces Management Changes and Company Updates

  • Appoints Interim CEO and CFO
  • Update on Timing of Form 10-Q Filing
  • Updated Company Address

IRVINE, Calif., June 4, 2014 -- Praxsyn Corporation (OTCQB:PAWS), a medication and service provider for medical practitioners, announced that Edward F. Kurtz, 51, has been elected to serve as the Company's Chief Operating Officer, which was effective on May 3, 2014. He was also appointed as Interim CEO, President and Chairman of the Board. Kurtz has more than 25 years of leadership experience in business development and operations, most recently in the strategic planning and growth of Mesa Pharmacy, a custom compounding pharmacy specializing in pain relief.

PraXsyn Announces That Its Subsidiary Mesa Pharmacy is Now Licensed in Illinois and Wisconsin

PALO ALTO, Calif., May 14, 2014 -- PraXsyn Corporation (OTCQB:PAWS), is pleased to announce that its pharmacy license applications, in the great State of Illinois and America's Dairyland, Wisconsin, were just approved.

"We are extremely excited to add these 2 great states to our list of states where we can dispense or ship medications. Together, these states have the potential of rivaling California as an extremely lucrative market for PraXsyn's pain management creams," said Dan Wiesel, CEO of PraXsyn. "PraXsyn's strategy is to provide an alternative to oral pain medications throughout the United States, and Illinois is just the first step in our expansion."

PraXsyn Sales Approximately $11M for April; Up From $8.8M in March

PALO ALTO, Calif., May 5, 2014 -- PraXsyn Corporation (OTCQB:PAWS) announces that after reporting March sales of $8.8M, April sales have increased to approximately $11M. "We are excited about the growth in sales, and we are looking forward to continued growth," said Dan Wiesel CEO of PraXsyn. Additionally, PraXsyn has asked DBB McKennon to become the company's new auditor. With the business in rapid growth, we felt that a local auditor would be more efficient working with the PraXsyn management team.